Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice
Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Rong Guo(Sun Yat-sen University), Yihong Ling(Sun Yat-sen University), Wan Yee Lau(Chinese University of Hong Kong), Ming Shi(Yanshan University), Ming Zhao(State Key Laboratory of Oncology in South China), Wei Wei(Zhujiang Hospital), Hongyan Liu(Jinan City People's Hospital), Zhixing Guo(Sun Yat-sen University), Feng Shi(Guangdong Academy of Medical Sciences), Xiaoming Chen(Guangdong Academy of Medical Sciences), Lianghe Lu(Sun Yat-sen University), Jie Mei(Sun Yat-sen University), Yabing Guo(Nanfang Hospital), Qiaoxuan Wang(Institute of Polymers)
Cited by 26
Related Papers
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial
|The Lancet|2004|895
A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2005|591
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.
|PubMed|1999|519
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346